AngioDynamics (NASDAQ:ANGO) Stock Price Expected to Rise, HC Wainwright Analyst Says

AngioDynamics (NASDAQ:ANGO) had its target price upped by equities research analysts at HC Wainwright from $16.00 to $19.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical instruments supplier’s stock. HC Wainwright’s target price points to a potential upside of 32.00% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Finally, Zacks Research lowered AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

AngioDynamics Stock Performance

Shares of ANGO stock traded up $1.39 during mid-day trading on Wednesday, hitting $14.39. 841,107 shares of the stock traded hands, compared to its average volume of 477,794. AngioDynamics has a twelve month low of $8.36 and a twelve month high of $14.80. The company’s 50-day simple moving average is $12.07 and its 200-day simple moving average is $11.32. The firm has a market cap of $594.76 million, a price-to-earnings ratio of -19.19 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts forecast that AngioDynamics will post -0.23 earnings per share for the current year.

Institutional Trading of AngioDynamics

Several large investors have recently added to or reduced their stakes in ANGO. Goldman Sachs Group Inc. grew its holdings in shares of AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares in the last quarter. Jane Street Group LLC boosted its position in AngioDynamics by 267.1% during the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after acquiring an additional 34,054 shares during the period. Legal & General Group Plc grew its stake in AngioDynamics by 279.5% during the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock valued at $123,000 after acquiring an additional 9,098 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of AngioDynamics by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after purchasing an additional 2,510 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of AngioDynamics by 15.8% in the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock valued at $960,000 after purchasing an additional 13,217 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics posted quarterly EPS of -$0.07, better than the expected -$0.11, while revenue of $86.61 million topped the consensus $80.24 million. Article Title
• Positive Sentiment: The company said fiscal 2026 was a record year and highlighted continued med-tech growth and full-year profitability, which supports the stock’s upward move. Article Title
• Positive Sentiment: Management raised fiscal 2027 revenue guidance to about $336 million-$341 million, above Wall Street expectations, suggesting momentum may continue. Article Title
• Neutral Sentiment: Despite the beat, AngioDynamics still reported a net loss and negative margins, so profitability remains a work in progress. Article Title
• Negative Sentiment: FY2027 EPS guidance of -$0.29 to -$0.24 was below the consensus view, which could temper some of the optimism around the strong revenue outlook. Article Title

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.